concluded that the microenvironment of TP53-mutated MDS has an immune-privileged, evasive phenotype that may be a primary driver of poor outcomes and suggested that immunomodulatory therapeutic strategies may improve survival in this molecularly defined subpopulation (20). This evidence concerns the gene TP53 and myelodysplastic syndrome.